AZ's Fasenra Hits First Hurdle Hard In COPD Study
Executive Summary
AstraZeneca’s bid to expand its respiratory biologic Fasenra from asthma into the chronic obstructive pulmonary disease space has been hurt by a Phase III failure but the company is holding its horses until the results of another large late-stage trial come in before the end of this quarter.
You may also be interested in...
AstraZeneca Looks To Challenge GSK’s Nucala With Fasenra EGPA Data
AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.
Anoro Comparisons Trip Up AZ’s Bevespi In Latest COPD Study
AstraZeneca has failed to show that its LAMA/LABA combo Bevespi Aerosphere is better than GSK’s Anoro Ellipta in a Phase IIIb study, a result “inconsistent” with previous data, but not surprising according to experts.
Q1 Preview: AstraZeneca’s Oncology Pipeline Center Stage As ASCO Approaches
Potential ASCO readouts and the recent setback for Fasenra in COPD will feature in AstraZeneca’s first quarter earnings presentation next week.